Saniona AB (publ) (STO:SANION)

Market Cap	3.02B
Revenue (ttm)	743.21M
Net Income (ttm)	573.47M
Shares Out	138.03M
EPS (ttm)	4.56
PE Ratio	4.80
Forward PE	9.73
Dividend	n/a
Ex-Dividend Date	n/a

Volume	247,205
Average Volume	935,476
Open	21.75
Previous Close	21.90
Day's Range	21.50 - 22.85
52-Week Range	5.41 - 23.65
Beta	1.32
RSI	55.88
Earnings Date	Feb 26, 2026

About Saniona AB

Saniona AB (publ), a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of treatments for rare disease patients in Sweden, the United States, Germany, Denmark, and the United Kingdom. It also develops medicines modulating ion channels. The company’s product includes Tesofensine, a monoamine reuptake inhibitor that has completed Phase 3 clinical trial to treat people with obesity; and Tesomet, an oral investigational therapy, which is in Phase 2b clinical trial for the treatment of hypothalamic ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2011
• Employees: 22
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: SANION